Assessment of the application of complimentary substances and methods in skin cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00003718

Enrollment

5000

Registered

2013-05-15

Start date

2011-09-21

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

scin cancer C43-C44

Interventions

Group 1: Questionnaire study: Patients are asked about the efficacy and safety of modern melanoma therapies under everyday conditions

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients with skin cancer who are advised and treated at a skin cancer center - A signed consent form - Age> 18 years

Exclusion criteria

Exclusion criteria: - Linguistic or other restrictions that prevent the independent completion of the questionnaire - Lack of informed consent

Design outcomes

Primary

Measure	Time frame
For each patient using a standardized questionnaire, the use of complementary and alternative therapies (CAM) is applicable. Patients when entering the skin cancer center will be asked regarding their treatment and aftercare at defined time points (1. admission to the skin cancer center, 2.: during treatment (number of surveys available, survey each in therapy change), 3. Aftercare () several surveys possible elevation at each follow-up visit. Data will be collected on larger collectives of different skin tumor entities on user behavior of patients from skin cancer centers in different provinces levied.	—

Measure

Time frame

For each patient using a standardized questionnaire, the use of complementary and alternative therapies (CAM) is applicable. Patients when entering the skin cancer center will be asked regarding their treatment and aftercare at defined time points (1. admission to the skin cancer center, 2.: during treatment (number of surveys available, survey each in therapy change), 3. Aftercare () several surveys possible elevation at each follow-up visit. Data will be collected on larger collectives of different skin tumor entities on user behavior of patients from skin cancer centers in different provinces levied.

—

Secondary

Measure	Time frame
The data on user behavior will be correlated to data for the individual patient's situation, history and treatment. 1. Motivation for the use of KAM 2. Influence of certain situations on the decision of therapy for patients KAM 3. Patient´s assessment regarding treatment efficacy 4. Extent of the potential interactions with anti-tumor therapy 5. Influence of the use of CAM in the course of therapy 6. Supportive effect of KAM 7. Negative effects of KAM on progression-free survival and overall survival 8. Evaluation of the questionnaire as a screening tool for the detection of user behavior regarding complementary and alternative therapies for skin cancer patients	—

Measure

Time frame

The data on user behavior will be correlated to data for the individual patient's situation, history and treatment. 1. Motivation for the use of KAM 2. Influence of certain situations on the decision of therapy for patients KAM 3. Patient´s assessment regarding treatment efficacy 4. Extent of the potential interactions with anti-tumor therapy 5. Influence of the use of CAM in the course of therapy 6. Supportive effect of KAM 7. Negative effects of KAM on progression-free survival and overall survival 8. Evaluation of the questionnaire as a screening tool for the detection of user behavior regarding complementary and alternative therapies for skin cancer patients

—

Countries

Germany

Contacts

Public ContactCarmen Loquai

Hautklinik und Poliklinik Universitätsmedizin Mainz der Johannes Gutenberg-Universität Mainz

carmen.loquai@ukmainz.deTel: 06131-17-6032

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026